Poster Session 1
Category: Clinical Obstetrics
Poster Session 1
Vajdana Tomić, MD, PhD
University of Mostar
University of Mostar, Federation of Bosnia and Herzegovina, Bosnia and Herzegovina
Dejan Tirić, MD
University of Mostar
University of Mostar, Federation of Bosnia and Herzegovina, Bosnia and Herzegovina
Nikolina Penava, MD
University of Mostar
University of Mostar, Federation of Bosnia and Herzegovina, Bosnia and Herzegovina
Ivona Šutalo Alilović, MD
University of Mostar
University of Mostar, Federation of Bosnia and Herzegovina, Bosnia and Herzegovina
Vedrana Mandrapa, MD
University of Mostar
University of Mostar, Federation of Bosnia and Herzegovina, Bosnia and Herzegovina
Ivona Margeta, MD
University of Mostar
University of Mostar, Federation of Bosnia and Herzegovina, Bosnia and Herzegovina
Ana Damjanović, MD
University of Mostar
University of Mostar, Federation of Bosnia and Herzegovina, Bosnia and Herzegovina
Mario Tomić, MD
University of Mostar
University of Mostar, Federation of Bosnia and Herzegovina, Bosnia and Herzegovina
Osoti Alfred, MBBCH, MEd, MPH, PhD
The University of Nairobi
The University of Nairobi, Nairobi Area, Kenya
Gwako John, MBBCH, MEd, PhD
MB,ChB, MMed,PhD
The University of Nairobi
The University of Nairobi, Nairobi Area, Kenya
Michael Stark
New European Surgical Academy
New European Surgical Academy, Berlin, Germany
Itamar Futterman, MD
Director, Complex Obstetrical Surgery, Maternal Fetal Medicine Attending
Maimonides Medical Center
Maimonides Health, New York, United States
Scott Chudnoff, MD
Chair, Dept of OBGYN
Maimonides Medical Center
Brooklyn, New York, United States
Agnes J. Karongo, MBBCH, MEd
The University of Nairobi
The University of Nairobi, Nairobi Area, Kenya
Wachira Kanyiri, MBBCH, MEd
The University of Nairobi
The University of Nairobi, North-Eastern, Kenya
Omondi Ogutu, MBBCH, MEd
The University of Nairobi
The University of Nairobi, Nairobi Area, Kenya
To evaluate the safety and performance of a novel vacuum-induced uterine tamponade device (Alma) for the treatment of postpartum hemorrhage (PPH) following failure of first-line medical treatment.
Study Design:
A prospective, open-label pilot study was conducted in two tertiary care centers between 04/2024-03/2025. Participants included patients with term pregnancies who were recruited upon arrival for delivery and who’s birthing process was complicated by PPH secondary to atony. Variables collected included time to bleeding control, blood loss, transfusion requirements, incidence of adverse events as well as usability ratings (scoring each of the following: setup, insertion, inflation, vacuum and deflation)
Results:
Sixteen (16) women with PPH following vaginal (n = 13) or cesarean (n = 3) delivery, who did not respond to standard first-line interventions, were treated using the Alma device. All 16 patients achieved prompt bleeding control, with restoration of uterine tone occurring within an average of 2.6 ± 0.8 minutes. The estimated blood loss prior to treatment averaged 878.1± 222.8 mL. The measured post-treatment blood loss averaged 115.5 ± 71.6 mL. No device-related complications or subsequent re-interventions were reported during 6-week follow-up. Red blood cell transfusions were administered in 7/16 (43.7%) of cases, while fresh frozen plasma was required in 4/16 (25.0%). Usability ratings were consistently high, with a mean score of 4.5/5 ±0.34 (Table 1).
Conclusion:
This study suggests that vacuum-induced uterine tamponade as applied using the Alma device, may offer a safe, rapid, and effective approach for controlling atonic PPH. Â Further, well designed, research is needed to assure product safety and effectiveness.